Duration of antibiotic therapy for XXXX . A randomized, double-blind, placebo-controlled trial.

@entity1 @entity2756 @entity3001 @entity294 @entity3403 @entity8831 @entity693
BACKGROUND: Treatment of @entity1 with @entity3001 has trended toward longer duration despite the absence of supporting clinical trials. OBJECTIVE: To evaluate different durations of oral @entity3403 treatment and the combination of oral @entity3403 and a single intravenous dose of @entity2756 for treatment of @entity1 with @entity3001 . DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Single-center university hospital. @entity1 : 180 @entity1 with @entity8831 . INTERVENTION: Ten days of oral @entity3403 , with or without a single intravenous dose of @entity2756 , or 20 days of oral @entity3403 . MEASUREMENTS: Outcome was based on clinical observations and neurocognitive testing. Efficacy was assessed at 20 days, 3 months, 12 months, and 30 months. RESULTS: At all time points, the complete response rate was similar for the three treatment groups in both on-study and intention-to-treat analyses. In the on-study analysis, the complete response rate at 30 months was 83.9% in the 20-day @entity3403 group, 90.3% in the 10-day @entity3403 group, and 86.5% in the @entity3403 - @entity2756 group (P > 0.2). The only @entity1 with treatment failure (10-day @entity3403 group) developed @entity693 on day 18. There were no significant differences in the results of neurocognitive testing among the three treatment groups and a separate control group without @entity3001 . @entity294 occurred significantly more often in the @entity3403 - @entity2756 group (35%) than in either of the other two groups (P < 0.001). CONCLUSIONS: Extending treatment with @entity3403 from 10 to 20 days or adding one dose of @entity2756 to the beginning of a 10-day course of @entity3403 did not enhance therapeutic efficacy in @entity1 with @entity8831 . Regardless of regimen, objective evidence of treatment failure was extremely rare.
